Who is eligible for clinical trial NCT05074355?

Participants must meet protocol criteria for Myeloproliferative Neoplasm. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05074355 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-02

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms (NCT05074355)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: University Health Network, Toronto

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (17 items).

Location: Princess Margaret Cancer Centre — Toronto, Ontario

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Ability to voluntarily provide written informed consent.
Documented diagnosis per World Health Organization (WHO) 2016 criteria of BCR-ABL negative myeloproliferative neoplasms (MPN).
Documented MPN transformation to accelerated phase (AP) or blast phase (BP) without prior blast reduction therapy for their AP/BP disease.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Adequate organ function.
Must practice at least one reliable method of birth-control starting at least on cycle 1 day 1 until at least 90 days after the last dose of study drug.
Female participants of childbearing potential must have a negative serum pregnancy test within 14 days prior to cycle 1 day 1.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
History of allogeneic stem cell transplant for MPN.
Previous treatment with venetoclax, navitoclax, azacytidine or other hypomethylating agents (HMA).
White blood cell count \>25 x 10\^9/L.
Current enrollment in another interventional study.
Presence of any active uncontrolled infection such as bacterial or fungal infections progressing despite adequate antimicrobial treatment.
Myocardial infarction in the preceding 3 months.
Active human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) infection.
History of active malignancy in the previous 2 years.
Any psychiatric illness or social circumstances or significant co-morbid conditions that may compromise study participation.
Pregnant or breastfeeding women.
Patients with known central nervous system (CNS) involvement with acute myeloid leukemia (AML) or CNS extramedullary hematopoiesis.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

Princess Margaret Cancer Centre — Toronto, Ontario

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗